Rautmann G, Daas A, Buchheit K-H
European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 7 allée Kastner, F-67081 Strasbourg, France,
European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 7 allée Kastner, F-67081 Strasbourg, France.
Pharmeur Bio Sci Notes. 2013;2013:93-111.
An international collaborative study was organised to establish the World Health Organization (WHO) 3(rd) International Standard (IS) for neomycin. Ten laboratories from different countries participated in the collaborative study. The potency of the candidate material, a freeze-dried preparation, was estimated by microbiological assays with sensitive micro-organisms. To ensure continuity between consecutive batches, the 2(nd) IS for neomycin was used as a standard. Based on the results of the study, the 3(rd) IS for neomycin was adopted at the meeting of the WHO Expert Committee on Biological Standardization (ECBS) in 2012 with an assigned potency of 19,050 IU per vial. The 3(rd) IS for neomycin is available from the European Directorate for the Quality of Medicines & HealthCare (EDQM).
组织了一项国际合作研究,以建立世界卫生组织(WHO)的新霉素第3个国际标准品(IS)。来自不同国家的10个实验室参与了这项合作研究。候选材料为冻干制剂,其效价通过使用敏感微生物的微生物学测定法进行估算。为确保连续批次之间的一致性,新霉素的第2个国际标准品用作标准。根据研究结果,新霉素第3个国际标准品于2012年在世卫组织生物标准化专家委员会(ECBS)会议上被采用,每瓶指定效价为19,050 IU。新霉素第3个国际标准品可从欧洲药品质量管理局(EDQM)获得。